NasdaqGM:PTGXBiotechs
Protagonist Therapeutics (PTGX) Swings To Net Income, Is The Valuation Too Expensive?
Protagonist Therapeutics (PTGX) has drawn fresh attention after reporting second quarter 2026 results that shifted from a net loss to net income of US$162.85 million, with earnings emerging from continuing operations.
See our latest analysis for Protagonist Therapeutics.
The sharp move from losses to net income has coincided with strong share price momentum for Protagonist Therapeutics, with a 90 day share price return of 40.94% and a year to date share price return of 67.32%. Over a longer...